Ric kayne files definitive proxy materials for athira's 2022 annual meeting

New york--(business wire)--richard a. (ric) kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of athira pharma, inc. (nasdaq: atha) (“athira” or the “company”), today filed a definitive proxy statement with the securities and exchange commission for the election of himself and george bickerstaff, iii, the former chief financial officer of novartis pharma ag, to athira's board of directors at the company's 2022 annual meeting o
ATHA Ratings Summary
ATHA Quant Ranking